GlassScriptPhysician profile
Cylburn Soden
NPI 1891976908
$200,792.25
in general payments reported to CMS, 2019-2025
46 companies · $77K in 2025
The $77K reported for 2025 was more than what 99% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $13K · 2021: $19K · 2022: $23K · 2023: $42K · 2024: $14K · 2025: $77K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $102K · Consulting Fee: $13K · Food and Beverage: $9,830 · Travel and Lodging: $7,700 · Education: $43.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $102,347.50 |
| Consulting Fee | $13,050.00 |
| Food and Beverage | $9,830.45 |
| Travel and Lodging | $7,700.35 |
| Education | $43.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $54,167.93 | 2019-2025 | Aklief, Epsolay, Oracea |
| Regeneron Healthcare Solutions, INC. | $42,509.97 | 2019-2025 | Dupixent, Libtayo |
| Incyte Corporation | $33,542.28 | 2021-2025 | Opzelura, Opzelura |
| Pfizer INC. | $17,542.77 | 2019-2025 | |
| Genzyme Corporation | $15,037.32 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $11,656.72 | 2023-2025 | Zoryve |
| Vyne Pharmaceuticals INC. | $10,841.39 | 2020-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $2,835.10 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Dermavant Sciences, INC. | $2,466.03 | 2022-2024 | Vtama |
| Abbvie INC. | $1,932.79 | 2019-2025 | Rinvoq, Skyrizi |
| Leo Pharma INC. | $1,531.94 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $1,150.47 | 2019-2025 | Tremfya |
| Mayne Pharma Commercial LLC | $933.92 | 2019-2023 | |
| Ucb, INC. | $557.50 | 2019-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $548.02 | 2019-2025 | Taltz, Olumiant, Ebglyss |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cylburn Soden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.